Nicotinamide Mmononucleotide in Patients Undergoing CABG Surgery

Launched by BRIGHAM AND WOMEN'S HOSPITAL · Jun 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a supplement called nicotinamide mononucleotide (NMN) on patients who are scheduled to undergo coronary artery bypass graft (CABG) surgery. CABG is a common heart surgery used to improve blood flow to the heart. Researchers want to see if taking NMN before surgery can help support heart and kidney health during recovery. The trial is designed to be fair, meaning that some participants will receive NMN, while others will receive a placebo (a pill that does not contain the active ingredient) without knowing which one they are getting.

To be eligible for this trial, participants must be at least 18 years old and scheduled for elective CABG surgery. They should also have certain health conditions that put them at higher risk for complications after surgery, such as being 65 years or older, having diabetes, or a history of heart issues. This trial is not yet recruiting participants, but if you qualify, you would receive detailed information about what to expect, including potential benefits and risks. It's an opportunity to contribute to important research that could improve care for future heart surgery patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years
• • 2. Scheduled to undergo elective isolated CABG surgery with cardiopulmonary bypass (CPB)
• 3. At increased risk of postoperative complications based on ≥1 of the following:
• • 1. Age ≥65 years
• • 2. eGFR \<45 ml/min/1.73m2
• • 3. Documented history of congestive heart failure or left ventricular ejection fraction (LVEF) ≤40% within 6 months before surgery
• • 4. Diabetes mellitus and urine albumin-to-creatinine ratio \>30 mg/g creatinine
• • 5. Peripheral arterial disease
• • 6. Anemia, defined as hemoglobin \<10 g/dl
• • 7. Prior cardiac surgery
• Exclusion Criteria:
• 1. Any of the following laboratory abnormalities at the time of screening:
• • 1. ALT \>3-fold the upper limit of normal
• • 2. eGFR \<30 ml/min/1.73m2 or ESKD on dialysis
• • 3. Hemoglobin \<8 g/dl
• • 2. History of gastric bypass or malabsorption
• • 3. Active alcohol or illicit substance use in the prior 6 months
• • 4. Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter
• • 5. Pregnant or breast-feeding
• • 6. Unwillingness to use contraception while taking study drug and for 8 weeks after the last dose for women of reproductive age or non-sterilized male participants who are sexually active with a female partner of childbearing potential
• • 7. Current use of niacin \>100 mg/day or NMN, nicotinamide, or nicotinamide riboside at any dose
• • 8. Conflict with other research studies
• • 9. Any condition which, in the judgement of the investigator, might increase the risk to the participant